Corrigendum to ‘Uniportal video-assisted thoracic surgery lobectomy: a consensus report from the Uniportal VATS Interest Group (UVIG) of the European Society of Thoracic Surgeons (ESTS)’  [Eur J Cardiothorac Surg 2019;56:224–9]

Bertolaccini, Luca; Batırel, Hasan Fevzi; Brunelli, Alessandro; González-Rivas, Diego; Ismail, Mahmoud; Ucar, Antonio Martin; Ng, Calvin S.H.; Scarci, Marco; Sihoe, Alan D. L.; Ugalde, Paula A.; Akar, Firas Abu; Bedetti, Benedetta; Nadal, Sergio Bolufer; Brandolini, Jury; Crucitti, Pierfilippo; Enyedi, Ágnes; Fernando, Hiran C.; Furák, József; Gallego-Poveda, Javier; Galvez-Munos, Carlos; Hanke, Ivo; Hernandez-Arenas, Luis Angel; Janík, Miroslav; Juhos, Peter; Libretti, Lidia; Lucciarini, Paolo; Macrì, Paolo; Margaritora, Stefano; Mahoozi, Hamid Reza; Nachira, Dania; Pardolesi, Alessandro; Pischik, Vadim; Sagan, Dariusz; Schreurs, Hermien; Sekhniaidze, Dmitrii; Socci, Laura; Tosi, Davide; Turna, Akif; Vannucci, Fernando; Zieliński, Marcin; Rocco, Gaetano

doi:10.1093/ejcts/ezz229

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, the efficacy of VATS in the treatment of lung cancer is comparable to standard thoracotomy ( 45 - 47 ). Single utility port thoracoscopic surgery is suitable for T-stage T 1 -T 3 (grade II) and N-stage N 0 -N 2 (grade I) lung cancer ( 43 , 48 ). Single utility port thoracoscopic lung surgery has the following advantages: Less bleeding, a shorter operative time and faster recovery than standard multiport thoracoscopic surgery ( 49 , 50 ).…”

Section: Nsclc Stages and Status Of Lung Cancer Surgerymentioning

confidence: 99%

Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review)

Hong

et al. 2022

Int J Oncol

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancer cases and has high morbidity and mortality rates. Over the past decade, treatment strategies for NSCLC have progressed rapidly, particularly with the increasing use of screening programs, leading to improvements in the initial diagnosis and treatment of early-stage and preinvasive tumors. Surgical intervention remains the primary treatment for early-stage NSCLC. Thoracoscopic lobectomy has become the main treatment for early-stage NSCLC, as it results in less postoperative bleeding and pain and fewer complications. However, the complication rate for thoracoscopic lobectomy due to sputum retention and weakened respiratory muscle strength remains as high as 19-59%. Treating NSCLC remains challenging in terms of postoperative pulmonary rehabilitation. In the present review, recent advances in postoperative pulmonary rehabilitation for patients with NSCLC were presented in order to assist researchers in developing improved treatments to enhance postoperative pulmonary rehabilitation for such patients. Contents 1. Introduction 2. NSCLC stages and status of lung cancer surgery 3. Postoperative pulmonary rehabilitation for patients with NSCLC 4. Current pulmonary rehabilitation for patients with NSCLC 5. Limitations of postoperative pulmonary rehabilitation 6. Conclusions and perspectives

show abstract

Section: Nsclc Stages and Status Of Lung Cancer Surgerymentioning

confidence: 99%

Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review)

Hong

et al. 2022

Int J Oncol

View full text Add to dashboard Cite

show abstract

Corrigendum to ‘Uniportal video-assisted thoracic surgery lobectomy: a consensus report from the Uniportal VATS Interest Group (UVIG) of the European Society of Thoracic Surgeons (ESTS)’ [Eur J Cardiothorac Surg 2019;56:224–9]

Abstract: on behalf of the Uniportal VATS Interest Group (UVIG) of the European Society of Thoracic Surgeons (ESTS)

Cited by 1 publication

References 0 publications

Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review)

Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review)

Contact Info

Product

Resources

About